W. Joseph Herring

Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial

David Michelson, Ellen Snyder, Erin M. Paradis et al. · The Lancet Neurology · 2014 · 503 citations

Sleep Medicine, Sleep, 1-Year Treatment +9

Orexin receptor antagonism for treatment of insomnia

W. Joseph Herring, Ellen Snyder, Kerry Budd et al. · Neurology · 2012 · 317 citations

Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials

W. Joseph Herring, Kathryn M. Connor, Neely Ivgy-May et al. · Biological Psychiatry · 2014 · 284 citations

Sleep Disorders, Sleep, Sleep Disorder +5

NMDA But Not Non-NMDA Excitotoxicity is Mediated by Poly(ADP-Ribose) Polymerase

Allen S. Mandir, Marc F. Poitras, Adam R. Berliner et al. · Journal of Neuroscience · 2000 · 213 citations · Full text

Molecular Biology, Cell Death, Enzymatic Modification +17

A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder

Lobna Ibrahim, Nancy Diazgranados, Libby Jolkovsky et al. · Journal of Clinical Psychopharmacology · 2012 · 212 citations

Psychotropic Medication, Psychopharmacology, Pharmacotherapy +16